Phase 2 clinical trial

Psychological distress is common in IBD and often goes unaddressed; a peer-led virtual program could expand access to emotional support and inform larger trials if found feasible and acceptable.

This trial tests an oral live biotherapeutic (MH002) aimed at restoring a healthier gut microbiome in people with mild-to-moderate ulcerative colitis. If effective and safe, it would offer a non-immunosuppressive,...

This trial tests standardized encapsulated fecal microbiota products as a microbiome-directed therapy for active Crohn’s disease, focusing on whether donor microbes engraft in the ileum and colon and whether that relates...

Patients with CGD can develop an IBD-like condition that is hard to treat because many immunosuppressive drugs raise infection risk. This trial suggests thalidomide may reduce intestinal inflammation in CGD-IBD without...

A controlled trial found low-dose naltrexone did not induce endoscopic or clinical remission in Crohn's disease, but it showed a possible benefit for reducing fatigue. Patients seeking symptom relief without...

This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...

Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...

People with UC have lower baseline gut microbial diversity and slower recovery after PEG bowel preparation; improving recovery of beneficial microbes could matter for symptom stability and gut health. This study suggests...

Sleep timing and morning light are modifiable, nonpharmacologic factors that could influence IBD quality of life and symptoms. If effective, a simple at-home light therapy could be an accessible adjunct to usual care.

This registry entry describes a completed Phase 2 study of a new IV drug (tulisokibart) for moderate–severe ulcerative colitis, including safety endpoints and a companion diagnostic — information patients may want when...

This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...

This observational study aims to link nutritional status and the dietary inflammatory potential to IBD activity and to test whether simple blood-derived inflammatory indices can serve as noninvasive markers of disease...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from...

People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...

New investigational therapy AZD7798 is being tested specifically for mucosal repair in people with active ileal Crohn’s disease who have an ileostomy — a group often excluded from other trials. Trial results could be...

Pouchitis is a common problem after colectomy with J‑pouch in ulcerative colitis and there are limited options to prevent it. If Aquamin® lowers inflammation or improves gut barrier measures, it could become a low‑risk...

Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...

This trial tests a non-drug way (virtual reality medical-hypnosis content) to reduce pain and embarrassment during rectosigmoidoscopy — a common, sometimes poorly tolerated procedure in ulcerative colitis that patients...

A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.

The study suggests a dietary/prebiotic compound (2'-FL) can change gut microbes and patient-reported disease control in mild-to-moderate UC, which could point to non-drug ways to support symptoms and microbiome health.

These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...

People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...

A pediatric Phase 2 trial testing etrasimod could expand treatment options for children with moderately to severely active ulcerative colitis if later shown safe and effective. Families of affected children and their...

Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.

Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...

The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.

The trial could show whether a smart-label app plus clinician alerts improves medication adherence and downstream clinical outcomes for people with Crohn's disease or ulcerative colitis starting oral or subcutaneous...

An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.

The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...

This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...

Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...

New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...

Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.

A new oral investigational therapy (TAK-279) is being tested in a randomized phase 2 trial for moderate–severe ulcerative colitis. Trial results could influence future treatment options if the drug proves safe and...

This pilot tests whether some patients with acute severe ulcerative colitis could avoid hospitalization by using early oral JAK inhibitor therapy plus steroids with close remote monitoring — a change that could reduce...

Patients and clinicians often want to know how quickly symptoms improve after starting a biologic. This study is designed to compare early patient‑reported symptom changes after starting vedolizumab versus IL‑23...

This registry will track how people with moderate to severe ulcerative colitis do on risankizumab in routine Japanese clinical practice, which may provide information about real-world remission rates and longer-term...

A new Phase 2 trial is testing SL-325 given IV for moderate-to-severe Crohn's disease with endoscopic response as the primary outcome. The study targets people who have not responded to or cannot tolerate several...

The study tests whether combining a standardized coping-skills program with biologic therapy improves emotional well-being and clinical/endoscopic outcomes in people with early Crohn's disease—addressing common...

Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...

If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from t.co.

Cure8 could only read part of this source from grafa.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...

If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...

This filing reports that PALI‑2108, an investigational oral PDE4 prodrug for IBD, showed encouraging Phase 1 signals and is moving into Phase 2 trials — a step toward more definitive efficacy data. The company also...

This trial tests a new oral drug, AC-101, for moderate-to-severe ulcerative colitis and may expand future treatment options if it proves effective and safe. The study targets patients who have failed or could not...

Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...